Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Dec 16:2019:3851576.
doi: 10.1155/2019/3851576. eCollection 2019.

Epithelial-Mesenchymal Transition in Skin Cancers: A Review

Affiliations
Review

Epithelial-Mesenchymal Transition in Skin Cancers: A Review

Anastasia Hodorogea et al. Anal Cell Pathol (Amst). .

Abstract

Epithelial-mesenchymal transition (EMT) is involved in physiologic processes such as embryogenesis and wound healing. A similar mechanism occurs in some tumors where cells leave the epithelial layer and gain mesenchymal particularities in order to easily migrate to other tissues. This process can explain the invasiveness and aggressiveness of these tumors which metastasize, by losing the epithelial phenotype (loss of E-cadherin, desmoplakin, and laminin-1) and acquiring mesenchymal markers (N-cadherin). Complex changes and interactions happen between the tumor cells and the microenvironment involving different pathways, transcription factors, altered expression of adhesion molecules, reorganization of cytoskeletal proteins, production of ECM-degrading enzymes, and changes in specific microRNAs. The purpose of this review is to determine particularities of the EMT process in the most common malignant cutaneous tumors (squamous cell carcinoma, basal cell carcinoma, and melanoma) which still have an increasingly high incidence. More studies are required on this topic in order to establish clear correlations. High costs related to skin cancer therapies in general as well as high impact on patients' quality of life demand finding new, reliable prognostic and therapeutic markers with significant public health impact.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Figures

Figure 1
Figure 1
Epithelial-mesenchymal transition hallmarks.
Figure 2
Figure 2
SCC cancer invasive front.
Figure 3
Figure 3
SOX2 pathway in cancer cells (a) vs. BCC cells (b).
Figure 4
Figure 4
Progression, migration, and invasion pathways in melanoma EMT.

Similar articles

Cited by

References

    1. Kalluri R., Robert A. The basics of epithelial-mesenchymal transition. Journal of Clinical Investigation. 2009;119(6):1420–1428. doi: 10.1172/JCI39104. - DOI - PMC - PubMed
    1. Pearlman R. L., Montes de Oca M. K., Pal H. C., Afaq F. Potential therapeutic targets of epithelial-mesenchymal transition in melanoma. Cancer Letters. 2017;(391):125–140. doi: 10.1016/j.canlet.2017.01.029. - DOI - PMC - PubMed
    1. Hollestelle A., Peeters J. K., Smid M., et al. Loss of E-cadherin is not a necessity for epithelial to mesenchymal transition in human breast cancer, Breast Cancer Research and Treatment. 2013;138(1):47–57. doi: 10.1007/s10549-013-2415-3. - DOI - PubMed
    1. Hülsken J., Birchmeier W., Behrens J. E-cadherin and APC compete for the interaction with beta-catenin and the cytoskeleton. The Journal of Cell Biology. 1994;127(6):2061–2069. doi: 10.1083/jcb.127.6.2061. - DOI - PMC - PubMed
    1. Grünert S., Jechlinger M., Beug H. Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nature Reviews Molecular Cell Biology. 2003;4(8):657–665. doi: 10.1038/nrm1175. - DOI - PubMed

MeSH terms